Phytochemicals as Lead Compounds in Pharmaceutical Development: Molecular Diversity, Drug-Likeness Optimization, and Translational Therapeutic Applications

Santosh Prasad Chaudhary Kurmi [1*], Shankar Thapa [2], Ashok Kumar Murav [3], Sharvendra Nath Maurya [4]
[1-4] Department of Pharmacy, Universal College of Medical Sciences, Bhairahawa, Nepal

* Corresponding Author: **Santosh Prasad Chaudhary Kurmi**

Article Info

ISSN (online): 3107-393X
Volume: 01
Issue: 01
January – February 2024
Received: 03-11-2023
Accepted: 05-12-2023
Published: 07-01-2024
Page No: 08-15

Abstract
Phytochemicals represent a privileged reservoir of structurally diverse chemical scaffolds that have historically served as templates for pharmaceutical innovation. Spanning alkaloids, terpenoids, polyphenols, and polyketides, these natural products exhibit exceptional molecular complexity and occupy pharmacologically relevant chemical space that remains underexplored by synthetic libraries. This review examines phytochemicals through the lens of contemporary drug discovery, focusing on their utility as lead compounds rather than botanical extracts. We discuss systematic approaches to lead identification, including target-based screening, phenotypic assays, and computational methods that leverage natural product databases for virtual screening. Key optimization strategies—including semi-synthesis, scaffold hopping, and fragment-based elaboration—are analyzed to address common limitations such as poor bioavailability, metabolic instability, and unfavorable physicochemical properties. Therapeutic applications span oncology, neurodegenerative disorders, metabolic diseases, and infectious diseases, with emphasis on mechanistic pharmacology and validated molecular targets. Critical translational barriers including supply chain sustainability, stereochemical complexity, and regulatory frameworks are evaluated alongside emerging solutions such as biosynthetic pathway engineering and AI-assisted retrosynthetic planning. The integration of multi-omics platforms, structure-based design, and patient stratification strategies promises to accelerate the clinical translation of phytochemical-derived therapeutics. This perspective underscores the enduring relevance of natural product chemistry in expanding druggable target space and delivering first-in-class pharmaceutical agents.

DOI:

Keywords: Phytochemicals; drug discovery; lead optimization; natural products; medicinal chemistry; translational pharmacology

1. Introduction

The pharmaceutical industry faces persistent challenges in identifying chemically novel scaffolds that can modulate previously undruggable targets while maintaining drug-like properties. Despite advances in combinatorial chemistry and fragment-based approaches, natural products—particularly those derived from plants—continue to serve as irreplaceable sources of molecular diversity [1, 2]. Phytochemicals have contributed approximately 25-50% of marketed drugs either as direct therapeutics, semi-synthetic derivatives, or pharmacophoric templates [3, 4]. Unlike synthetic libraries that typically explore limited chemical space defined by sp^2-rich aromatic cores, phytochemicals exhibit high sp^3 content, multiple stereocenters, and conformational rigidity that enhance target selectivity and reduce off-target toxicity [5].

The evolution from ethnopharmacological observations to mechanism-driven drug discovery has fundamentally transformed how phytochemicals are evaluated. Modern approaches prioritize molecular target validation, structure-activity relationship (SAR) elucidation, and pharmacokinetic optimization over empirical screening of crude extracts [6, 7]. This paradigm shift is supported by technological advances including high-throughput screening (HTS), fragment-growing strategies, and computational docking algorithms that can predict binding modes with increasing accuracy [8].

This review synthesizes current knowledge on phytochemical-based pharmaceutical development, emphasizing lead identification workflows, optimization strategies to overcome ADMET (absorption, distribution, metabolism, excretion, toxicity) liabilities, and translational pathways from preclinical validation to clinical application. We analyze major phytochemical classes, their molecular mechanisms, and therapeutic domains while critically evaluating barriers that impede their progression through drug development pipelines.

2. Phytochemicals as Drug Discovery Leads

Phytochemicals occupy privileged structural space characterized by molecular features that synthetic chemistry rarely generates spontaneously. Analysis of natural product databases reveals higher scaffold diversity, greater stereochemical complexity (average of 6-8 chiral centers per molecule), and broader distribution across Lipinski's rule of five parameters compared to conventional synthetic libraries [9, 10]. These characteristics confer both advantages and challenges. The structural complexity enables exquisite target selectivity—exemplified by taxol's unique binding mode within β-tubulin polymers—but simultaneously creates synthetic accessibility problems and formulation difficulties [11].

Lead identification from phytochemical sources employs multiple complementary strategies. Target-based screening utilizes purified enzymes or receptors in biochemical assays, enabling rapid throughput but requiring prior target validation [12]. Phenotypic screening using cellular models offers the advantage of identifying compounds with acceptable permeability and polypharmacology, though mechanistic elucidation requires subsequent target deconvolution [13]. Reverse pharmacology approaches analyze traditional uses to generate hypotheses about molecular targets, followed by rigorous biochemical validation [14].

The concept of "privileged scaffolds"—structural motifs that bind multiple unrelated protein families—has proven particularly valuable in phytochemical-based discovery [15]. Flavonoid, isoquinoline, and indole frameworks exemplify such scaffolds, appearing across diverse therapeutic targets including kinases, proteases, and G-protein coupled receptors (GPCRs). Recognition of these patterns enables focused library synthesis around validated pharmacophores while exploring substitution patterns that modulate selectivity profiles.

Phytochemicals also serve as starting points for fragment-based drug discovery (FBDD), where complex molecules are deconstructed into minimal binding units that retain target engagement [16]. These fragments undergo iterative elaboration using structure-guided design, often yielding more drug-like derivatives than the parent natural product. This approach has successfully generated clinical candidates from resveratrol and curcumin scaffolds with improved potency and metabolic stability [17].

3. Major Classes of Bioactive Phytochemicals

3.1. Alkaloids

Alkaloids constitute nitrogen-containing heterocyclic compounds with extraordinary structural diversity and potent pharmacological activities [18]. Vincristine and vinblastine, isolated from *Catharanthus roseus*, bind the vinca domain of tubulin, disrupting microtubule dynamics and inducing mitotic arrest in rapidly dividing cells [19]. These compounds exemplify how phytochemicals can achieve mechanisms distinct from synthetic anticancer agents. Berberine, an isoquinoline alkaloid, demonstrates multitarget activity including AMP-activated protein kinase (AMPK) activation and inhibition of protein tyrosine phosphatase 1B (PTP1B), positioning it as a scaffold for metabolic disease therapeutics [20].

The tropane alkaloid atropine functions as a competitive muscarinic acetylcholine receptor antagonist, illustrating how alkaloid scaffolds can achieve receptor subtype selectivity through conformational constraints [21]. Morphine and related opiates remain irreplaceable analgesics despite extensive medicinal chemistry efforts to replicate their μ-opioid receptor binding profile, underscoring the challenges in replacing natural product complexity [22].

3.2. Terpenoids

Terpenoids, derived from isoprene units, span diverse structures from monoterpenes to triterpenes. Paclitaxel (Taxol®) stabilizes microtubules through binding at the taxane site on β-tubulin, a mechanism fundamentally different from vinca alkaloids [23]. Semi-synthetic modifications yielding docetaxel improved solubility and metabolic stability while maintaining the core pharmacophore [24]. Artemisinin, a sesquiterpene lactone endoperoxide, generates carbon-centered radicals upon iron-catalyzed cleavage, alkylating heme and parasitic proteins [25]. Its synthetic derivative artemether addresses bioavailability limitations of the parent compound.

Betulinic acid and related pentacyclic triterpenes exhibit selective cytotoxicity toward melanoma cells through mitochondrial membrane disruption and topoisomerase inhibition [26]. Chemical modifications at the C-3 and C-28 positions have yielded derivatives with nanomolar potencies and improved pharmacokinetic profiles.

3.3. Polyphenols

Polyphenolic compounds, including flavonoids, stilbenes, and lignans, demonstrate broad biological activities mediated by antioxidant capacity, kinase inhibition, and epigenetic modulation [27]. Epigallocatechin gallate (EGCG) from green tea inhibits multiple kinases including EGFR, VEGFR, and PI3K through ATP-competitive binding, though poor bioavailability (< 5%) limits clinical translation [28]. Prodrug strategies including peracetylated derivatives have shown improved oral absorption.

Resveratrol activates sirtuins, particularly SIRT1, influencing metabolic pathways and cellular senescence [29]. However, rapid glucuronidation and sulfation necessitate structural modifications to enhance systemic exposure. Scaffold hopping to indole-containing analogs has generated compounds with improved pharmacokinetics while retaining SIRT1 activation.

Quercetin functions as a bioflavonoid with anti-inflammatory properties through NF-κB pathway inhibition and mast cell stabilization [30]. Its glycosylation status profoundly affects absorption, with rutin (quercetin-3-rutinoside) exhibiting superior bioavailability compared to the aglycone form.

3.4. Polyketides

Polyketides represent structurally complex metabolites synthesized through iterative condensation reactions. Lovastatin, isolated from *Monascus* species, competitively inhibits HMG-CoA reductase, representing the prototype for statin drugs [31]. Semi-synthetic atorvastatin incorporates fluorophenyl substituents that enhance potency and extend half-life. The immunosuppressant rapamycin binds FKBP12, with the resulting complex inhibiting mTOR (mammalian target of rapamycin), demonstrating allosteric modulation mechanisms uncommon in synthetic drugs [32].

Table 1: Representative Phytochemical Classes and Lead Compounds

Phytochemical Class	Representative Compound	Chemical Scaffold	Molecular Target	Therapeutic Application
Vinca Alkaloids	Vincristine	Dimeric indole	β-tubulin vinca domain	Acute lymphoblastic leukemia
Taxanes	Paclitaxel	Tricyclic diterpene	β-tubulin taxane site	Breast, ovarian cancer
Artemisinin Derivatives	Artemether	Sesquiterpene endoperoxide	Heme, PfATP6	Antimalarial
Polyphenols	EGCG	Catechin gallate	EGFR, VEGFR kinases	Cancer chemoprevention
Statins	Lovastatin	Polyketide lactone	HMG-CoA reductase	Hypercholesterolemia
Camptothecins	Topotecan	Quinoline alkaloid	Topoisomerase I	Ovarian, small cell lung cancer

4. Modern Strategies for Phytochemical Drug Development

4.1. Structure-Activity Relationship Studies

SAR analysis identifies pharmacophoric elements essential for target binding while revealing positions amenable to modification [33]. Systematic variation of substituents, stereochemistry, and functional groups generates structure-activity landscapes that guide optimization. For camptothecin analogs, modifications at the C-7, C-9, and C-10 positions improved water solubility and lactone ring stability, yielding topotecan and irinotecan with superior clinical profiles [34].

Computational docking coupled with molecular dynamics simulations predicts binding modes and residence times, enabling virtual screening of derivative libraries before synthesis [35]. Machine learning models trained on phytochemical bioactivity data can identify non-intuitive modifications that enhance potency or selectivity.

4.2. Semi-Synthesis and Total Synthesis

Semi-synthesis leverages abundant phytochemicals as starting materials for chemical elaboration, reducing cost and environmental impact compared to total synthesis [36]. Artemisinin semi-synthesis produces artemether, artesunate, and artemotere with improved pharmaceutical properties. Total synthesis becomes necessary when natural abundance is insufficient or when extensive structural modifications are required. The total synthesis of Taxol® enabled structure-function studies but proved economically nonviable for commercial production, leading to semi-synthesis from 10-deacetylbaccatin III [37].

Biosynthetic pathway engineering in microbial hosts offers an alternative production route. Heterologous expression of plant biosynthetic gene clusters in yeast or bacteria can generate phytochemical scaffolds amenable to biotransformation or direct pharmaceutical use [38].

4.3. Drug-Likeness Optimization

Many phytochemicals violate Lipinski's rule of five, exhibiting high molecular weights (> 500 Da), excessive hydrogen bond donors/acceptors, and poor lipophilicity profiles [39]. Optimization strategies include:

1. **Prodrug derivatization:** Esterification or glycosylation masks polar functionalities, improving membrane permeability with subsequent enzymatic activation *in vivo*
2. **Scaffold simplification:** Removal of non-essential structural elements reduces molecular complexity while retaining pharmacophore integrity
3. **PEGylation and nanoformulation:** Polymeric conjugates or liposomal encapsulation enhance circulation time and tumor accumulation through enhanced permeability and retention (EPR) effects [40]

For curcumin, over 40 clinical trials have been conducted, yet poor bioavailability (< 1%) limits efficacy. Strategies including micellar formulations, piperine co-administration to inhibit glucuronidation, and structural analogs with blocked metabolic sites have shown clinical promise [41].

4.4. Fragment-Based and Hybrid Approaches

Deconstruction of complex phytochemicals into minimal binding fragments enables library expansion using medicinal chemistry principles [42]. Fragment-linking or fragment-growing strategies guided by X-ray crystallography generate optimized ligands. Hybrid molecules combining pharmacophores from distinct phytochemical classes exploit synergistic mechanisms. Combretastatin-chalcone hybrids merge tubulin-binding motifs from combretastatin with anti-inflammatory properties of chalcones, yielding dual-action anticancer agents [43].



Fig 1: Integrated Workflow for Phytochemical-Based Drug Discovery

5. Therapeutic Applications

5.1. Oncology

Phytochemical-derived anticancer agents account for over 60% of FDA-approved oncology drugs [44]. Mechanisms span microtubule disruption (taxanes, vinca alkaloids), topoisomerase inhibition (camptothecins, podophyllotoxin derivatives), and kinase modulation (flavonoids). Etoposide, derived from podophyllotoxin, stabilizes topoisomerase II-DNA cleavage complexes, inducing double-strand breaks [45]. Clinical use in testicular cancer and small cell lung cancer demonstrates the translational success of natural product optimization.

Combretastatin A-4 phosphate (CA4P) functions as a vascular disrupting agent, selectively destroying tumor neovasculature through tubulin binding and endothelial cell shape changes [46]. Phase III trials in anaplastic thyroid cancer highlight its potential as combination therapy.

5.2. Neurodegenerative Disorders

Galantamine, an alkaloid from *Galanthus* species, competitively inhibits acetylcholinesterase while allosterically modulating nicotinic acetylcholine receptors [47]. FDA approval for Alzheimer's disease symptom management validates phytochemical applications in neurodegeneration. Huperzine A, from *Huperzia serrata*, demonstrates superior blood-brain barrier penetration and longer duration of action compared to synthetic cholinesterase inhibitors [48].

Curcumin analogs targeting amyloid-β aggregation and tau phosphorylation are under clinical investigation, with modifications addressing metabolic instability [49].

5.3. Metabolic Diseases

Metformin, though synthetically produced, derives from galegine found in *Galega officinalis* [50]. Its mechanism involving AMPK activation and mitochondrial complex I inhibition has spawned extensive medicinal chemistry efforts. Berberine demonstrates comparable glycemic control through multitarget effects including gut microbiota modulation and incretin secretion enhancement [51].

5.4. Infectious Diseases

Quinine established the antimalarial paradigm, with subsequent development of chloroquine and mefloquine [52]. Artemisinin-based combination therapies (ACTs) remain first-line treatment for *Plasmodium falciparum* malaria, with resistance management strategies involving partner drugs. Antiviral phytochemicals targeting viral entry (griffithsin against HIV gp120) and replication (silvestrol inhibiting eIF4A helicase) represent emerging therapeutic avenues [53, 54].

Table 2: Molecular Mechanisms and Validated Targets of Phytochemical Leads

Compound	Primary Target	Mechanism of Action	Downstream Effects	Clinical Status
Paclitaxel	β-tubulin	Microtubule stabilization	Mitotic arrest, apoptosis	FDA approved
Artemisinin	Heme, PfATP6	Radical generation, Ca^{2+} dysregulation	Parasite death	WHO essential medicine
Galantamine	AChE, nAChR	Competitive inhibition, allosteric modulation	Enhanced cholinergic transmission	FDA approved (AD)
Etoposide	Topoisomerase II	DNA cleavage complex stabilization	Double-strand breaks	FDA approved
Berberine	AMPK, PTP1B	Kinase activation, phosphatase inhibition	Glucose uptake, insulin sensitivity	Investigational

Table 3: Therapeutic Indications of Phytochemical-Derived Drugs

Therapeutic Area	Representative Drugs	Target Disease	Development Stage
Oncology	Vincristine, paclitaxel, etoposide	Leukemia, solid tumors	Marketed
Infectious Disease	Artemether, quinine	Malaria	Marketed
Neurology	Galantamine, huperzine A	Alzheimer's disease	Marketed/Phase III
Cardiology	Lovastatin, atorvastatin	Hyperlipidemia	Marketed
Immunology	Rapamycin derivatives	Transplant rejection	Marketed
Pain Management	Morphine, codeine	Acute/chronic pain	Marketed



Fig 2: Phytochemical Classes Mapped to Molecular Target Families

6. Challenges and Translational Barriers

6.1. Supply and Sustainability

Natural product supply chains face challenges including species endangerment, seasonal variability, and geopolitical instability [55]. Paclitaxel's initial isolation from *Taxus brevifolia* bark required destructive harvesting, prompting development of semi-synthetic routes from renewable *Taxus* needle material. Plant cell culture and hairy root systems offer controlled production environments but often yield lower titers than field-grown plants [56].

6.2. Structural Complexity and Synthesis

The average phytochemical contains 8-12 stereocenters, creating synthetic challenges that increase cost and limit scalability [57]. Total synthesis campaigns may require 30-50 steps with overall yields below 1%, rendering them impractical for commercial manufacturing. Chemoenzymatic synthesis combining chemical steps with biocatalytic transformations offers improved efficiency for stereoselective reactions [58].

6.3. Physicochemical and ADMET Liabilities

High molecular weight, poor aqueous solubility, and rapid first-pass metabolism frequently limit oral bioavailability [59]. Curcumin undergoes extensive glucuronidation and sulfation, achieving plasma concentrations in the nanomolar range despite gram-level dosing. P-glycoprotein efflux further reduces intracellular accumulation of many phytochemicals. Formulation strategies including cyclodextrin complexation, solid dispersions, and self-emulsifying drug delivery systems partially address solubility issues [60].

6.4. Intellectual Property and Regulatory Pathways

Natural products cannot be patented, necessitating protection of synthetic derivatives, formulations, or therapeutic applications. Regulatory agencies require demonstration of safety and efficacy through conventional clinical trial pathways, with no abbreviated approval routes despite traditional use histories. Standardization of phytochemical preparations remains problematic due to batch-to-batch variability in plant secondary metabolites.

Table 4: Advantages, Limitations, and Development Challenges in Phytochemical Drug Discovery

Aspect	Advantages	Limitations	Mitigation Strategies
Chemical Diversity	High sp^3 content, stereochemical complexity	Synthetic accessibility challenges	Semi-synthesis, biosynthesis
Target Selectivity	Evolved binding to biological macromolecules	Off-target effects possible	SAR optimization, selectivity profiling
Bioavailability	Membrane-permeable scaffolds (some)	Poor solubility, rapid metabolism	Prodrugs, nanoformulation
Supply	Renewable biological sources	Sustainability, standardization issues	Cell culture, metabolic engineering
IP Protection	Derivative patentability	Natural products unpatentable	Formulation patents, new indications



Fig 3: Translational Progression from Lead Optimization to Clinical Application

7. Future Perspectives

Integration of artificial intelligence and machine learning into natural product discovery accelerates hit identification and optimization. Algorithms trained on phytochemical-target interaction databases predict bioactivity profiles for untested compounds, prioritizing synthesis candidates. Generative models propose novel analogs with optimized drug-like properties while maintaining pharmacophoric features.

Multi-omics approaches combining genomics, transcriptomics, and metabolomics enable systems-level understanding of phytochemical mechanisms. Network pharmacology reveals polypharmacology patterns and identifies synergistic combination partners. CRISPR-based genome editing in plant hosts facilitates pathway engineering to enhance yields of target metabolites or generate novel derivatives through combinatorial biosynthesis.

Precision medicine strategies will increasingly leverage pharmacogenomic data to identify patient populations most likely to benefit from phytochemical therapeutics. Biomarker-driven clinical trials reduce heterogeneity and improve success rates. Tumor organoid models and patient-derived xenografts enable preclinical efficacy testing in genetically diverse backgrounds, predicting clinical response patterns.

Advances in green chemistry and flow chemistry reduce environmental impact of phytochemical synthesis while improving scalability. Continuous manufacturing platforms enable real-time quality control and reduce batch failures. Three-dimensional bioprinting may eventually produce complex botanical tissues for sustainable phytochemical harvesting.

8. Conclusion

Phytochemicals remain indispensable to pharmaceutical innovation, providing chemically diverse scaffolds that expand druggable target space beyond the reach of conventional synthetic chemistry. Their successful translation requires abandoning traditional herbal medicine frameworks in favor of rigorous target validation, mechanism-based optimization, and pharmacokinetic engineering. While challenges in synthesis, bioavailability, and supply sustainability persist, emerging technologies including biosynthetic pathway engineering, AI-assisted drug design, and precision formulation strategies offer viable solutions.

The therapeutic impact of phytochemical-derived drugs—from cancer chemotherapy to antimalarials to immunosuppressants—demonstrates their clinical value. Future success will depend on interdisciplinary collaboration integrating natural product chemistry, structural biology, computational modeling, and translational pharmacology. As high-throughput omics platforms and machine learning algorithms mature, the systematic mining of plant metabolomes for pharmaceutical leads will accelerate, ensuring that phytochemicals continue to contribute disproportionately to the global pharmacopeia.

9. References

1. Newman DJ, Cragg GM. Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. J Nat Prod. 2020;83(3):770–803.
2. Atanasov AG, Zotchev SB, Dirsch VM, Supuran CT. Natural products in drug discovery: advances and opportunities. Nat Rev Drug Discov. 2021;20(3):200–16.
3. Harvey AL, Edrada-Ebel R, Quinn RJ. The re-emergence of natural products for drug discovery in the genomics era. Nat Rev Drug Discov. 2015;14(2):111–29.

4. Rodrigues T, Reker D, Schneider P, Schneider G. Counting on natural products for drug design. Nat Chem. 2016;8(6):531–41.
5. Lovering F, Bikker J, Humblet C. Escape from flatland: increasing saturation as an approach to improving clinical success. J Med Chem. 2009;52(21):6752–6.
6. Swinney DC, Anthony J. How were new medicines discovered? Nat Rev Drug Discov. 2011;10(7):507–19.
7. Koehn FE, Carter GT. The evolving role of natural products in drug discovery. Nat Rev Drug Discov. 2005;4(3):206–20.
8. Scior T, Bender A, Tresadern G, Medina-Franco JL. Recognizing pitfalls in virtual screening: a critical review. J Chem Inf Model. 2012;52(4):867–81.
9. Ertl P, Roggo S, Schuffenhauer A. Natural product-likeness score and its application for prioritization of compound libraries. J Chem Inf Model. 2008;48(1):68–74.
10. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001;46(1–3):3–26.
11. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly *in vitro* by taxol. Nature. 1979;277(5698):665–7.
12. Macarron R, Banks MN, Bojanic D, *et al*. Impact of high-throughput screening in biomedical research. Nat Rev Drug Discov. 2011;10(3):188–95.
13. Moffat JG, Vincent F, Lee JA, Eder J, Prunotto M. Opportunities and challenges in phenotypic drug discovery: an industry perspective. Nat Rev Drug Discov. 2017;16(8):531–43.
14. Vaidya AD, Devasagayam TP. Current status of herbal drugs in India: an overview. J Clin Biochem Nutr. 2007;41(1):1–11.
15. Welsch ME, Snyder SA, Stockwell BR. Privileged scaffolds for library design and drug discovery. Curr Opin Chem Biol. 2010;14(3):347–61.
16. Erlanson DA, Fesik SW, Hubbard RE, Jahnke W, Jhoti H. Twenty years on: the impact of fragments on drug discovery. Nat Rev Drug Discov. 2016;15(9):605–19.
17. Gupta SC, Patchva S, Aggarwal BB. Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J. 2013;15(1):195–218.
18. Cushnie TP, Cushnie B, Lamb AJ. Alkaloids: an overview of their antibacterial, antibiotic-enhancing and antivirulence activities. Int J Antimicrob Agents. 2014;44(5):377–86.
19. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer. 2004;4(4):253–65.
20. Yin J, Xing H, Ye J. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism. 2008;57(5):712–7.
21. Kruse AC, Kobilka BK, Gautam D, Sexton PM, Christopoulos A, Wess J. Muscarinic acetylcholine receptors: novel opportunities for drug development. Nat Rev Drug Discov. 2014;13(7):549–60.
22. Pasternak GW, Pan YX. Mu opioids and their receptors: evolution of a concept. Pharmacol Rev. 2013;65(4):1257–317.
23. Weaver BA. How Taxol/paclitaxel kills cancer cells. Mol Biol Cell. 2014;25(18):2677–81.
24. Bissery MC, Guénard D, Guéritte-Voegelein F, Lavelle F. Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res. 1991;51(18):4845–52.
25. Meshnick SR. Artemisinin: mechanisms of action, resistance and toxicity. Int J Parasitol. 2002;32(13):1655–60.
26. Pisha E, Chai H, Lee IS, *et al*. Discovery of betulinic acid as a selective inhibitor of human melanoma that functions by induction of apoptosis. Nat Med. 1995;1(10):1046–51.
27. Scalbert A, Johnson IT, Saltmarsh M. Polyphenols: antioxidants and beyond. Am J Clin Nutr. 2005;81(1 Suppl):215S–17S.
28. Shankar S, Ganapathy S, Srivastava RK. Green tea polyphenols: biology and therapeutic implications in cancer. Front Biosci. 2007;12:4881–99.
29. Howitz KT, Bitterman KJ, Cohen HY, *et al*. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature. 2003;425(6954):191–6.
30. Mlcek J, Jurikova T, Skrovankova S, Sochor J. Quercetin and its anti-allergic immune response. Molecules. 2016;21(5):623.
31. Endo A. A historical perspective on the discovery of statins. Proc Jpn Acad Ser B Phys Biol Sci. 2010;86(5):484–93.
32. Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. Cell. 2017;168(6):960–76.
33. Wermuth CG. Similarity in drugs: reflections on analogue design. Drug Discov Today. 2006;11(7–8):348–54.
34. Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer. 2006;6(10):789–802.
35. Sliwoski G, Kothiwale S, Meiler J, Lowe EW Jr. Computational methods in drug discovery. Pharmacol Rev. 2014;66(1):334–95.
36. Chen QH, Kingston DG, Porco JA Jr. Recent advances in semisynthetic modification of bioactive natural products. Prog Chem Org Nat Prod. 2013;97:1–43.
37. Holton RA, Somoza C, Kim HB, *et al*. First total synthesis of taxol. J Am Chem Soc. 1994;116(4):1597–8.
38. Paddon CJ, Keasling JD. Semi-synthetic artemisinin: a model for the use of synthetic biology in pharmaceutical development. Nat Rev Microbiol. 2014;12(5):355–67.
39. Doak BC, Over B, Giordanetto F, Kihlberg J. Oral druggable space beyond the rule of 5: insights from drugs and clinical candidates. Chem Biol. 2014;21(9):1115–42.
40. Anselmo AC, Mitragotri S. Nanoparticles in the clinic: an update. Bioeng Transl Med. 2019;4(3):e10143.
41. Hewlings SJ, Kalman DS. Curcumin: a review of its effects on human health. Foods. 2017;6(10):92.
42. Murray CW, Rees DC. The rise of fragment-based drug discovery. Nat Chem. 2009;1(3):187–92.
43. La Regina G, Sarkar T, Bai R, *et al*. New arylthioindoles and related bioisosteres at the sulfur bridging group. J Med Chem. 2009;52(23):7512–27.
44. Cragg GM, Newman DJ. Plants as a source of anti-cancer agents. J Ethnopharmacol. 2005;100(1–2):72–9.
45. Hande KR. Etoposide: four decades of development of a topoisomerase II inhibitor. Eur J Cancer. 1998;34(10):1514–21.

46. Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat Rev Cancer. 2005;5(6):423–35.
47. Maelicke A, Samochocki M, Jostock R, *et al*. Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease. Biol Psychiatry. 2001;49(3):279–88.
48. Wang R, Yan H, Tang XC. Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine. Acta Pharmacol Sin. 2006;27(1):1–26.
49. Mishra S, Palanivelu K. The effect of curcumin (turmeric) on Alzheimer's disease: an overview. Ann Indian Acad Neurol. 2008;11(1):13–19.
50. Bailey CJ, Day C. Metformin: its botanical background. Pract Diabetes Int. 2004;21(3):115–7.
51. Zhang Y, Li X, Zou D, *et al*. Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. J Clin Endocrinol Metab. 2008;93(7):2559–65.
52. Achan J, Talisuna AO, Erhart A, *et al*. Quinine, an old anti-malarial drug in a modern world: role in the treatment of malaria. Malar J. 2011;10:144.
53. Millet JK, Séron K, Labitt RN, *et al*. Middle East respiratory syndrome coronavirus infection is inhibited by griffithsin. Antiviral Res. 2016;133:1–8.
54. Biedenkopf N, Lange-Grünweller K, Schulte FW, *et al*. The natural compound silvestrol is a potent inhibitor of Ebola virus replication. Antiviral Res. 2017;137:76–81.
55. Chen SL, Yu H, Luo HM, *et al*. Conservation and sustainable use of medicinal plants: problems, progress, and prospects. Chin Med. 2016;11:37.
56. Karuppusamy S. A review on trends in production of secondary metabolites from higher plants by *in vitro* tissue, organ and cell cultures. J Med Plants Res. 2009;3(13):1222–39.
57. Nicolaou KC, Yang Z, Liu JJ, *et al*. Total synthesis of taxol. Nature. 1994;367(6464):630–4.
58. Schrittwieser JH, Velikogne S, Hall M, Kroutil W. Artificial biocatalytic linear cascades for preparation of organic molecules. Chem Rev. 2018;118(1):270–348.
59. van de Waterbeemd H, Gifford E. ADMET in silico modelling: towards prediction paradise? Nat Rev Drug Discov. 2003;2(3):192–204.
60. Kalepu S, Nekkanti V. Insoluble drug delivery strategies: review of recent advances and business prospects. Acta Pharm Sin B. 2015;5(5):442–53.